Company Overview and News
The past few quarters have seen a marked resurgence in activity and investment in unconventional oil and gas basins in the United States. So much so that discussions about decline curves and pipeline capacity have also resurfaced. Some industry watchers have said pipeline relief in key shale basins may not happen until 2020. Despite these challenges, smaller companies to well-known behemoths like Exxon Mobil Corp.
The U.S. Energy Information Administration (EIA) released its weekly petroleum status report Wednesday morning showing that U.S. commercial crude inventories decreased by 5.9 million barrels last week, maintaining a total U.S. commercial crude inventory of 426.5 million barrels. The commercial crude inventory is about 2% below the five-year average for this time of year.
Investors looking for stocks in the Oil and Gas - Integrated - International sector might want to consider either Shell Oil (RDS.A - Free Report) or Chevron (CVX - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
It was a week where oil prices extended their recent declines but natural gas futures moved above the critical $3 threshold.
XOM EEXXQ VLO MPC EXXI NEE.PRI BHI NEE.PRJ EGC EXXIQ NEE.PRC EXIXQ CVX NEE.PRQ NEE.PRR RIG PAA NEE SGAZF
Chicago, IL – June 19, 2018 – Zacks Equity Research highlights QuinStreet (QNST - Free Report) as the Bull of the Day and Ambarella (AMBA - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amazon (AMZN - Free Report) , Chevron (CVX - Free Report) and Mastercard (MA - Free Report) .
HD DB CVX MA AMBA PKD APR APRLY QNST RCKY
We’ve never been fans of direct commodities investments and have been warning about the lack of risk adjusted returns that commodities funds offer investors for years. In previous articles, we focused on the structural issues with commodities markets and commodities funds that make them unworthy of inclusion in investors’ portfolios. In this article, we want to focus on a different aspect of commodities funds that make them unattractive.
HAL RIO RIO BLT XOM APD PSX COP SHW RTPPF RTNTF VDE BHPBF VLO DWDP VALE PPG PX BHP RIO CVX DBC VAW BBL BHP PDBC SLB BHPLF AI
Energy XXI Gulf Coast, Inc. (EGC - Free Report) recently inked a deal, per which privately held Dallas-based operator Cox Oil Offshore LLC will acquire the former. Apart from expanding Cox’s presence in the Gulf of Mexico (GoM), the acquisition also offers Energy XXI the much-needed respite and best solution to maximize its shareholders’ value amid its distressing financials. The move was hugely appreciated by the investors of Energy XXI, as evidenced by its share-price uptick post the announcement.
MS.PRE EEXXQ FCX MS.PRF MS.PRG BCEI MS.PRA EXXI EGC EXXIQ MS.PRI MS.PRK EXIXQ CVX MS
On Jun 22, a congregation of OPEC (Oil and Petroleum Exporting Countries) countries and non- OPEC allies will assemble in Vienna to take a decision regarding an 18-month old agreement to curb output in order to support global oil prices. Notably, Saudi Arabia and Russia are extremely eager to dissolve the production barrier. However, some OPEC members, especially Iran, Iraq, Venezuela and Iraq are in favor of maintaining status quo.
COP XOM CVX OXY
Boeing, which has acted as a proxy for trade war tensions with China as it is the single largest US exporter to the country, fell 0.9 per cent as the biggest drag on the Dow.
The Dow and S&P were modestly lower on Monday, having recovered from earlier lows, as gains in energy shares helped curb declines stemming from trade war concerns after China's retaliation to US tariffs.
NEW YORK, June 19 — The Dow and S&P fell modestly yesterday, ending well off session lows, as gains in energy shares helped curb declines stemming from trade war concerns after China's retaliation to US tariffs.
NEW YORK (June 19): The Dow and S&P fell modestly on Monday, ending well off session lows, as gains in energy shares helped curb declines stemming from trade war concerns after China's retaliation to U.S. tariffs.
U.S. stocks fell at the open on Monday as a trade dispute between the United States and China intensified following Beijing's retaliation to tariffs imposed by President Donald Trump.
RIO DE JANEIRO/HOUSTON, June 8 (Reuters) - U.S. oil producer Chevron Corp has permanently assigned its Brazil country chief to run its Venezuelan operations after the months-long detention of two executives escalated tensions between the OPEC-member nation and foreign oil firms.
SLB RDS.B RDS.A CVX RYDBF RDSB SCL RDSA SLB RYDAF
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to CVX / Chevron Corp. on message board site Silicon Investor.
as of ET